Hedge Fund - Copernicus Capital Management

Manager biography is currently missing.

Fund Profile

Filing Period:

Fund Name:	Copernicus Capital Management
Manager	John W. Rende
Portfolio Value	$6,416,000
Change This QTR	+0.06%

Top 13F Holdings

Filing Period:

Last updated on February 16, 2021, 9:07 pm based on SEC 13F filings Last update: February 16, 2021, 9:07 pm

No.	Security	Ticker	Shares	Value (x$1000)	Activity	% Port
1.	Biomarin Pharmaceutical Inc	BMRN	10,719	$940	-94%	14.65%
2.	Vertex Pharmaceuticals Inc / Ma	VRTX	3,085	$729	-94%	11.36%
3.	Bristol Myers Squibb Co	BMY	11,327	$703	-95%	10.95%
4.	Abbvie Inc.	ABBV	4,676	$501	-97%	7.8%
5.	Rocket Pharmaceuticals Inc.	RCKT	8,000	$439	NEW	6.84%